{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:17:48Z","timestamp":1771543068667,"version":"3.50.1"},"reference-count":55,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MBE"],"published-print":{"date-parts":[[2022]]},"abstract":"<abstract>\n\t\t\t<p>Tumor mutation burden (TMB), an emerging molecular determinant, is accompanied by microsatellite instability and immune infiltrates in various malignancies. However, whether TMB is related to the prognosis or immune responsiveness of adrenocortical carcinoma (ACC) remains to be elucidated. This paper aims to investigate the impact of TMB on the prognosis and immune microenvironment infiltration in ACC. The somatic mutation data, gene expression profile, and corresponding clinicopathological information were retrieved from TCGA. The mutation landscape was summarized and visualized with the waterfall diagram. The ACC patients were divided into low and high TMB groups based on the median TMB value and differentially expressed genes (DEGs) between the two groups were identified. Diverse functional analyses were conducted to determine the functionality of the DEGs. The immune cell infiltration signatures were evaluated based on multiple algorithms. Eventually, a TMB Prognostic Signature (TMBPS) was established and its predictive accuracy for ACC was evaluated. Single nucleotide polymorphism and C &gt; T were found to be more common than other missense mutations. In addition, lower TMB levels indicated improved survival outcomes and were correlated with younger age and earlier clinical stage. Functional analysis suggested that DEGs were primarily related to the cell cycle, DNA replication, and cancer progression. Additionally, significant differences in infiltration levels of activated CD4+ T cells, naive B cells, and activated NK cells were observed in two TMB groups. We also found that patients with higher TMBPS showed worse survival outcomes, which was validated in the Gene Expression Omnibus database. Our study systematically analyzed the mutation and identified a TMBPS combined with immune microenvironment infiltration in ACC. It is expected that this paper can promote the development of ACC treatment strategies.<\/p>\n\t\t<\/abstract><\/jats:p>","DOI":"10.3934\/mbe.2022333","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T10:33:30Z","timestamp":1652351610000},"page":"7055-7075","source":"Crossref","is-referenced-by-count":3,"title":["Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma"],"prefix":"10.3934","volume":"19","author":[{"given":"Yong","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingbiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2321","reference":[{"key":"key-10.3934\/mbe.2022333-1","doi-asserted-by":"publisher","unstructured":"J. Crona, F. Beuschlein, Adrenocortical carcinoma\u2014towards genomics guided clinical care, Nat<\/i>. Rev<\/i>. Endocrinol.<\/i>, 15<\/b> (2019), 548-560. https:\/\/doi.org\/10.1038\/s41574-019-0221-7","DOI":"10.1038\/s41574-019-0221-7"},{"key":"key-10.3934\/mbe.2022333-2","doi-asserted-by":"publisher","unstructured":"G. G. F. Ranvier, W. B. R. Inabnet, Surgical management of adrenocortical carcinoma, Endocrinol. Metab. Clin.<\/i>, 44<\/b> (2015), 435-452. https:\/\/doi.org\/10.1016\/j.ecl.2015.02.008","DOI":"10.1016\/j.ecl.2015.02.008"},{"key":"key-10.3934\/mbe.2022333-3","doi-asserted-by":"publisher","unstructured":"N. Georgantzoglou, S. Kokkali, G. Tsourouflis, S. Theocharis, Tumor microenvironment in adrenocortical carcinoma: Barrier to immunotherapy success, Cancers<\/i>, 13<\/b> (2021), 1798. https:\/\/doi.org\/10.3390\/cancers13081798","DOI":"10.3390\/cancers13081798"},{"key":"key-10.3934\/mbe.2022333-4","doi-asserted-by":"publisher","unstructured":"M. Fassnacht, S. Johanssen, M. Quinkler, P. Bucsky, H. S. Willenberg, F. Beuschlein, et al., Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: Proposal for a revised TNM classification, Cancer<\/i>, 115<\/b> (2009), 243-250. https:\/\/doi.org\/10.1002\/cncr.24030","DOI":"10.1002\/cncr.24030"},{"key":"key-10.3934\/mbe.2022333-5","doi-asserted-by":"publisher","unstructured":"G. Assi\u00e9, A. Jouinot, M. Fassnacht, R. Lib\u00e9, S. Garinet, L. Jacob, et al., Value of molecular classification for prognostic assessment of adrenocortical carcinoma, JAMA Oncol<\/i>.<\/i>, 5<\/b> (2019), 1440-1447. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1558","DOI":"10.1001\/jamaoncol.2019.1558"},{"key":"key-10.3934\/mbe.2022333-6","doi-asserted-by":"publisher","unstructured":"P. Zhao, L. Li, X. Jiang, Q. Li, Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy, J. Hematol. Oncol.<\/i>, 12<\/b> (2019), 54. https:\/\/doi.org\/10.1186\/s13045-019-0738-1","DOI":"10.1186\/s13045-019-0738-1"},{"key":"key-10.3934\/mbe.2022333-7","doi-asserted-by":"publisher","unstructured":"S. T. Paijens, A. Vledder, M. de Bruyn, H. W. Nijman, Tumor-infiltrating lymphocytes in the immunotherapy era, Cell. Mol. Immunol.<\/i>, 18<\/b> (2021), 842-859. https:\/\/doi.org\/10.1038\/s41423-020-00565-9","DOI":"10.1038\/s41423-020-00565-9"},{"key":"key-10.3934\/mbe.2022333-8","doi-asserted-by":"publisher","unstructured":"T. A. Chan, M. Yarchoan, E. Jaffee, C. Swanton, S. A. Quezada, A. Stenzinger, et al., Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic, Ann. Oncol., 30 (2019), 44-56. https:\/\/doi.org\/10.1093\/annonc\/mdy495","DOI":"10.1093\/annonc\/mdy495"},{"key":"key-10.3934\/mbe.2022333-9","doi-asserted-by":"publisher","unstructured":"S. E. Stanton, M. L. Disis, Clinical significance of tumor-infiltrating lymphocytes in breast cancer, J. Immunother. Cancer, 4 (2016), 59. https:\/\/doi.org\/10.1186\/s40425-016-0165-6","DOI":"10.1186\/s40425-016-0165-6"},{"key":"key-10.3934\/mbe.2022333-10","doi-asserted-by":"publisher","unstructured":"R. M. Bremnes, L. Busund, T. L. Kilv\u00e6r, S. Andersen, E. Richardsen, E. E. Paulsen, et al., The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer, J. Thorac. Oncol.<\/i>, 11<\/b> (2016), 789-800. https:\/\/doi.org\/10.1016\/j.jtho.2016.01.015","DOI":"10.1016\/j.jtho.2016.01.015"},{"key":"key-10.3934\/mbe.2022333-11","doi-asserted-by":"publisher","unstructured":"M. Poch, M. Hall, A. Joerger, K. Kodumudi, M. Beatty, P. P. Innamarato, et al., Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer, Oncoimmunology<\/i>, 7<\/b> (2018), e1476816. https:\/\/doi.org\/10.1080\/2162402X.2018.1476816","DOI":"10.1080\/2162402X.2018.1476816"},{"key":"key-10.3934\/mbe.2022333-12","doi-asserted-by":"publisher","unstructured":"L. Ye, T. Zhang, Z. Kang, G. Guo, Y. Sun, K. Lin, et al., Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer, Front. Immunol.<\/i>, 10<\/b> (2019), 2368. https:\/\/doi.org\/10.3389\/fimmu.2019.02368","DOI":"10.3389\/fimmu.2019.02368"},{"key":"key-10.3934\/mbe.2022333-13","doi-asserted-by":"publisher","unstructured":"X. Tian, W. Xu, Y. Wang, A. Anwaier, H. Wang, F. Wan, et al., Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: Results from bioinformatics and real-world data, Oncoimmunology<\/i>, 9<\/b> (2020), 1784529. https:\/\/doi.org\/10.1080\/2162402X.2020.1784529","DOI":"10.1080\/2162402X.2020.1784529"},{"key":"key-10.3934\/mbe.2022333-14","doi-asserted-by":"publisher","unstructured":"L. Fancello, S. Gandini, P. G. Pelicci, L. Mazzarella, Tumor mutational burden quantification from targeted gene panels: major advancements and challenges, J. Immunother. Cancer<\/i>, 7<\/b> (2019), 183. https:\/\/doi.org\/10.1186\/s40425-019-0647-4","DOI":"10.1186\/s40425-019-0647-4"},{"key":"key-10.3934\/mbe.2022333-15","doi-asserted-by":"publisher","unstructured":"C. Luo, J. Chen, L. Chen, Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer, Int. Immunopharmacol.<\/i>, 86<\/b> (2020), 106709. https:\/\/doi.org\/10.1016\/j.intimp.2020.106709","DOI":"10.1016\/j.intimp.2020.106709"},{"key":"key-10.3934\/mbe.2022333-16","doi-asserted-by":"publisher","unstructured":"H. Zhou, L. Chen, Y. Lei, T. Li, H. Li, X. Cheng, Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer, Curr. Probl. Cancer<\/i>, 45<\/b> (2021), 100660. https:\/\/doi.org\/10.1016\/j.currproblcancer.2020.100660","DOI":"10.1016\/j.currproblcancer.2020.100660"},{"key":"key-10.3934\/mbe.2022333-17","doi-asserted-by":"publisher","unstructured":"N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J. J. Havel, et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science<\/i>, 348<\/b> (2015), 124-128. https:\/\/doi.org\/10.1126\/science.aaa1348","DOI":"10.1126\/science.aaa1348"},{"key":"key-10.3934\/mbe.2022333-18","doi-asserted-by":"publisher","unstructured":"M. D. Hellmann, T. Ciuleanu, A. Pluzanski, J. S. Lee, G. A. Otterson, C. Audigier-Valette, et al., Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden, N. Engl. J. Med.<\/i>, 378<\/b> (2018), 2093-2104. https:\/\/doi.org\/10.1056\/NEJMoa1801946","DOI":"10.1056\/NEJMoa1801946"},{"key":"key-10.3934\/mbe.2022333-19","doi-asserted-by":"publisher","unstructured":"M. D. Hellmann, M. K. Callahan, M. M. Awad, E. Calvo, P. A. Ascierto, A. Atmaca, et al., Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer, Cancer Cell<\/i>, 33<\/b> (2018), 853-861. https:\/\/doi.org\/10.1016\/j.ccell.2018.04.001","DOI":"10.1016\/j.ccell.2018.04.001"},{"key":"key-10.3934\/mbe.2022333-20","doi-asserted-by":"publisher","unstructured":"C. Zhang, Z. Li, F. Qi, X. Hu, J. Luo, Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma, Ann. Transl. Med.<\/i>, 7<\/b> (2019), 648. https:\/\/doi.org\/10.21037\/atm.2019.10.84","DOI":"10.21037\/atm.2019.10.84"},{"key":"key-10.3934\/mbe.2022333-21","doi-asserted-by":"publisher","unstructured":"J. Yan, X. Wu, J. Yu, Y. Zhu, S. Cang, Prognostic role of tumor mutation burden combined with immune infiltrates in skin cutaneous melanoma based on multi-omics analysis, Front. Oncol.<\/i>, 10<\/b> (2020), 570654. https:\/\/doi.org\/10.3389\/fonc.2020.570654","DOI":"10.3389\/fonc.2020.570654"},{"key":"key-10.3934\/mbe.2022333-22","doi-asserted-by":"publisher","unstructured":"J. D. Wasserman, A. Novokmet, C. Eichler-Jonsson, R. C. Ribeiro, C. Rodriguez-Galindo, G. P. Zambetti, et al., Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: A children's oncology group study, J. Clin. Oncol.<\/i>, 33<\/b> (2015), 602-609. https:\/\/doi.org\/10.1200\/JCO.2013.52.6863","DOI":"10.1200\/JCO.2013.52.6863"},{"key":"key-10.3934\/mbe.2022333-23","doi-asserted-by":"publisher","unstructured":"N. Riaz, L. Morris, J. J. Havel, V. Makarov, A. Desrichard, T. A. Chan, The role of neoantigens in response to immune checkpoint blockade, Int. Immunol.<\/i>, 28<\/b> (2016), 411-419. https:\/\/doi.org\/10.1093\/intimm\/dxw019","DOI":"10.1093\/intimm\/dxw019"},{"key":"key-10.3934\/mbe.2022333-24","doi-asserted-by":"publisher","unstructured":"D. A. Braun, K. P. Burke, E. M. Van Allen, Genomic approaches to understanding response and resistance to immunotherapy, Clin. Cancer Res.<\/i>, 22<\/b> (2016), 5642-5650. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0066","DOI":"10.1158\/1078-0432.CCR-16-0066"},{"key":"key-10.3934\/mbe.2022333-25","doi-asserted-by":"publisher","unstructured":"A. Mayakonda, D. Lin, Y. Assenov, C. Plass, H. P. Koeffler, Maftools: Efficient and comprehensive analysis of somatic variants in cancer, Genome Res.<\/i>, 28<\/b> (2018), 1747-1756. https:\/\/doi.org\/10.1101\/gr.239244.118","DOI":"10.1101\/gr.239244.118"},{"key":"key-10.3934\/mbe.2022333-26","doi-asserted-by":"publisher","unstructured":"M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, et al., Limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res.<\/i>, 43<\/b> (2015), e47. https:\/\/doi.org\/10.1093\/nar\/gkv007","DOI":"10.1093\/nar\/gkv007"},{"key":"key-10.3934\/mbe.2022333-27","doi-asserted-by":"crossref","unstructured":"Gene Ontology Consortium<\/i>, Gene Ontology Consortium: Going forward, Nucleic Acids Res.<\/i>, 43<\/b> (2015), D1049-D1056. https:\/\/doi.org\/10.1093\/nar\/gku1179<\/a>","DOI":"10.1093\/nar\/gku1179"},{"key":"key-10.3934\/mbe.2022333-28","doi-asserted-by":"publisher","unstructured":"G. Yu, L. Wang, Y. Han, Q. He, ClusterProfiler: An R package for comparing biological themes among gene clusters, Omics: J. Integr. Biol.<\/i>, 16<\/b> (2012), 284-287. https:\/\/doi.org\/10.1089\/omi.2011.0118","DOI":"10.1089\/omi.2011.0118"},{"key":"key-10.3934\/mbe.2022333-29","doi-asserted-by":"publisher","unstructured":"M. Kanehisa, S. Goto, KEGG: Kyoto encyclopedia of genes and genomes, Nucleic Acids Res.<\/i>, 28<\/b> (2000), 27-30. https:\/\/doi.org\/10.1093\/nar\/28.1.27","DOI":"10.1093\/nar\/28.1.27"},{"key":"key-10.3934\/mbe.2022333-30","doi-asserted-by":"publisher","unstructured":"A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci.<\/i>, 102<\/b> (2005), 15545-15550. https:\/\/doi.org\/10.1073\/pnas.0506580102","DOI":"10.1073\/pnas.0506580102"},{"key":"key-10.3934\/mbe.2022333-31","doi-asserted-by":"publisher","unstructured":"K. A. Zalocusky, M. J. Kan, Z. Hu, P. Dunn, E. Thomson, J. Wiser, et al., The 10,000 immunomes project: Building a resource for human immunology, Cell Rep.<\/i>, 25<\/b> (2018), 513-522. https:\/\/doi.org\/10.1016\/j.celrep.2018.09.021","DOI":"10.1016\/j.celrep.2018.09.021"},{"key":"key-10.3934\/mbe.2022333-32","doi-asserted-by":"publisher","unstructured":"B. Chen, M. S. Khodadoust, C. L. Liu, A. M. Newman, A. A. Alizadeh, Profiling tumor infiltrating immune cells with CIBERSORT, Methods<\/i> Mol. Biol.<\/i>, 1711<\/b> (2018), 243-259. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_12","DOI":"10.1007\/978-1-4939-7493-1_12"},{"key":"key-10.3934\/mbe.2022333-33","doi-asserted-by":"publisher","unstructured":"Y. Ma, X. Feng, W. Yang, C. You, Exploring the pathological mechanism of bladder cancer based on tumor mutational burden analysis, Biomed. Res. Int.<\/i>, 2019<\/b> (2019), 1093815. https:\/\/doi.org\/10.1155\/2019\/1093815","DOI":"10.1155\/2019\/1093815"},{"key":"key-10.3934\/mbe.2022333-34","doi-asserted-by":"publisher","unstructured":"S. Turajlic, A. Sottoriva, T. Graham, C. Swanton, Resolving genetic heterogeneity in cancer, Nat. Rev. Genet.<\/i>, 20<\/b> (2019), 404-416. https:\/\/doi.org\/10.1038\/s41576-019-0114-6","DOI":"10.1038\/s41576-019-0114-6"},{"key":"key-10.3934\/mbe.2022333-35","doi-asserted-by":"publisher","unstructured":"Y. Ino, R. Yamazaki-Itoh, K. Shimada, M. Iwasaki, T. Kosuge, Y. Kanai, et al., Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer, Br. J. Cancer<\/i>, 108<\/b> (2013), 914-923. https:\/\/doi.org\/10.1038\/bjc.2013.32","DOI":"10.1038\/bjc.2013.32"},{"key":"key-10.3934\/mbe.2022333-36","doi-asserted-by":"publisher","unstructured":"M. V. Dieci, F. Miglietta, V. Guarneri, Immune infiltrates in breast cancer: Recent updates and clinical implications, Cells<\/i>, 10<\/b> (2021). https:\/\/doi.org\/10.3390\/cells10020223","DOI":"10.3390\/cells10020223"},{"key":"key-10.3934\/mbe.2022333-37","doi-asserted-by":"publisher","unstructured":"X. Liu, S. Wu, Y. Yang, M. Zhao, G. Zhu, Z. Hou, The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer, Biomed. Pharmacother.<\/i>, 95<\/b> (2017), 55-61. https:\/\/doi.org\/10.1016\/j.biopha.2017.08.003","DOI":"10.1016\/j.biopha.2017.08.003"},{"key":"key-10.3934\/mbe.2022333-38","doi-asserted-by":"publisher","unstructured":"E. Billon, P. Finetti, A. Bertucci, P. Niccoli, D. Birnbaum, E. Mamessier, et al., PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma, Oncoimmunology<\/i>, 8<\/b> (2019), e1655362. https:\/\/doi.org\/10.1080\/2162402X.2019.1655362","DOI":"10.1080\/2162402X.2019.1655362"},{"key":"key-10.3934\/mbe.2022333-39","doi-asserted-by":"publisher","unstructured":"C. Zhang, L. Shen, F. Qi, J. Wang, J. Luo, Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma, J. Cell. Physiol.<\/i>, 235<\/b> (2020), 3849-3863. https:\/\/doi.org\/10.1002\/jcp.29279","DOI":"10.1002\/jcp.29279"},{"key":"key-10.3934\/mbe.2022333-40","doi-asserted-by":"publisher","unstructured":"K. Sakai, M. Tsuboi, H. Kenmotsu, T. Yamanaka, T. Takahashi, K. Goto, et al., Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR), Cancer Sci.<\/i>, 112<\/b> (2021), 388-396. https:\/\/doi.org\/10.1111\/cas.14730","DOI":"10.1111\/cas.14730"},{"key":"key-10.3934\/mbe.2022333-41","doi-asserted-by":"publisher","unstructured":"T. Jiang, J. Shi, Z. Dong, L. Hou, C. Zhao, X. Li, et al., Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma, J. Hematol. Oncol.<\/i>, 12<\/b> (2019), 75. https:\/\/doi.org\/10.1186\/s13045-019-0762-1","DOI":"10.1186\/s13045-019-0762-1"},{"key":"key-10.3934\/mbe.2022333-42","doi-asserted-by":"publisher","unstructured":"A. Parrales, T. Iwakuma, Targeting oncogenic mutant p53 for cancer therapy, Front. Oncol.<\/i>, 5<\/b> (2015), 288. https:\/\/doi.org\/10.3389\/fonc.2015.00288","DOI":"10.3389\/fonc.2015.00288"},{"key":"key-10.3934\/mbe.2022333-43","doi-asserted-by":"publisher","unstructured":"M. Kanapathipillai, Treating p53 mutant aggregation-associated cancer, Cancers<\/i>, 10<\/b> (2018). https:\/\/doi.org\/10.3390\/cancers10060154","DOI":"10.3390\/cancers10060154"},{"key":"key-10.3934\/mbe.2022333-44","doi-asserted-by":"publisher","unstructured":"A. Chassot, M. Le Rolle, M. Jourden, M. M. Taketo, N. B. Ghyselinck, M. Chaboissier, Constitutive WNT\/CTNNB1 activation triggers spermatogonial stem cell proliferation and germ cell depletion, Dev. Biol.<\/i>, 426<\/b> (2017), 17-27. https:\/\/doi.org\/10.1016\/j.ydbio.2017.04.010","DOI":"10.1016\/j.ydbio.2017.04.010"},{"key":"key-10.3934\/mbe.2022333-45","doi-asserted-by":"publisher","unstructured":"D. Messerschmidt, W. N. de Vries, C. Lorthongpanich, S. Balu, D. Solter, B. B. Knowles, \u0392-catenin-mediated adhesion is required for successful preimplantation mouse embryo development, Development<\/i>, 143<\/b> (2016), 1993-1999. https:\/\/doi.org\/10.1242\/dev.133439","DOI":"10.1242\/dev.133439"},{"key":"key-10.3934\/mbe.2022333-46","doi-asserted-by":"publisher","unstructured":"S. Devarakonda, F. Rotolo, M. Tsao, I. Lanc, E. Brambilla, A. Masood, et al., Tumor mutation burden as a biomarker in resected non-small-cell lung cancer, J. Clin. Oncol.<\/i>, 36<\/b> (2018), 2995-3006. https:\/\/doi.org\/10.1200\/JCO.2018.78.1963","DOI":"10.1200\/JCO.2018.78.1963"},{"key":"key-10.3934\/mbe.2022333-47","doi-asserted-by":"publisher","unstructured":"X. Wang, M. Li, Correlate tumor mutation burden with immune signatures in human cancers, BMC Immunol.<\/i>, 20<\/b> (2019), 4. https:\/\/doi.org\/10.1186\/s12865-018-0285-5","DOI":"10.1186\/s12865-018-0285-5"},{"key":"key-10.3934\/mbe.2022333-48","doi-asserted-by":"publisher","unstructured":"H. Kitao, M. Iimori, Y. Kataoka, T. Wakasa, E. Tokunaga, H. Saeki, et al., DNA replication stress and cancer chemotherapy, Cancer Sci.<\/i>, 109<\/b> (2018), 264-271. https:\/\/doi.org\/10.1111\/cas.13455","DOI":"10.1111\/cas.13455"},{"key":"key-10.3934\/mbe.2022333-49","doi-asserted-by":"publisher","unstructured":"S. Zheng, A. D. Cherniack, N. Dewal, R. A. Moffitt, L. Danilova, B. A. Murray, et al., Comprehensive pan-genomic characterization of adrenocortical carcinoma, Cancer Cell<\/i>, 29<\/b> (2016), 723-736. https:\/\/doi.org\/10.1016\/j.ccell.2016.04.002","DOI":"10.1016\/j.ccell.2016.04.002"},{"key":"key-10.3934\/mbe.2022333-50","doi-asserted-by":"publisher","unstructured":"M. Ingham, G. K. Schwartz, Cell-cycle therapeutics come of age, J. Clin. Oncol.<\/i>, 35<\/b> (2017), 2949-2959. https:\/\/doi.org\/10.1200\/JCO.2016.69.0032","DOI":"10.1200\/JCO.2016.69.0032"},{"key":"key-10.3934\/mbe.2022333-51","doi-asserted-by":"publisher","unstructured":"M. Zhu, W. Xu, C. Wei, J. Huang, J. Xu, Y. Zhang, et al., CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis, Cell Death Dis.<\/i>, 10<\/b> (2019), 796. https:\/\/doi.org\/10.1038\/s41419-019-1966-6","DOI":"10.1038\/s41419-019-1966-6"},{"key":"key-10.3934\/mbe.2022333-52","doi-asserted-by":"publisher","unstructured":"L. Xu, W. Yu, H. Xiao, K. Lin, BIRC5 is a prognostic biomarker associated with tumor immune cell infiltration, Sci. Rep.<\/i>, 11<\/b> (2021), 1-13. https:\/\/doi.org\/10.1038\/s41598-020-79736-7","DOI":"10.1038\/s41598-020-79736-7"},{"key":"key-10.3934\/mbe.2022333-53","doi-asserted-by":"publisher","unstructured":"Y. Vahidi, Z. Faghih, A. Talei, M. Doroudchi, A. Ghaderi, Memory CD4(+) T cell subsets in tumor draining lymph nodes of breast cancer patients: A focus on T stem cell memory cells, Cell. Oncol.<\/i>, 41<\/b> (2018), 1-11. https:\/\/doi.org\/10.1007\/s13402-017-0352-6","DOI":"10.1007\/s13402-017-0352-6"},{"key":"key-10.3934\/mbe.2022333-54","doi-asserted-by":"publisher","unstructured":"K. Hiraoka, M. Miyamoto, Y. Cho, M. Suzuoki, T. Oshikiri, Y. Nakakubo, et al., Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma, Br. J. Cancer<\/i>, 94<\/b> (2006), 275-280. https:\/\/doi.org\/10.1038\/sj.bjc.6602934","DOI":"10.1038\/sj.bjc.6602934"},{"key":"key-10.3934\/mbe.2022333-55","doi-asserted-by":"publisher","unstructured":"L. E. Harrington, K. M. Janowski, J. R. Oliver, A. J. Zajac, C. T. Weaver, Memory CD4 T cells emerge from effector T-cell progenitors, Nature<\/i>, 452<\/b> (2008), 356-360. https:\/\/doi.org\/10.1038\/nature06672","DOI":"10.1038\/nature06672"}],"container-title":["Mathematical Biosciences and Engineering"],"original-title":[],"link":[{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/mbe.2022333?viewType=html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T01:17:37Z","timestamp":1652923057000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/mbe.2022333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3934\/mbe.2022333","relation":{},"ISSN":["1551-0018"],"issn-type":[{"value":"1551-0018","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}